Oxana Beskrovnaya, Ph.D.Chief Scientific Officer at Dyne Therapeutics
An accomplished R&D leader with a track record of discovering and developing first-in-class therapeutics for rare genetic diseases, Dr. Beskrovnaya has worked across multiple disease indications in both large biopharmaceutical and small biotech companies. She is currently chief scientific officer at Dyne Therapeutics where she leads research focused on antibody-driven delivery of oligonucleotides for the treatment of genetically driven diseases. Prior to joining Dyne, Oxana served as head of musculoskeletal and renal research in Sanofi’s rare disease and neurological unit, advancing a pipeline of drug candidates using multiple therapeutic modalities including nucleic acids, proteins and small molecules. Previously, Oxana served in various capacities of increasing responsibility at Genzyme, where she managed research in genetics, disease mechanisms, target discovery/validation and translational biomarkers in rare renal, metabolic, skeletal and neuromuscular diseases. Oxana has authored numerous patents, invited reviews, editorials, book chapters and original research articles in major scientific journals including Nature, Nature Medicine, Cell and Molecular Cell. Oxana received her doctorate in genetics from Moscow Genetics Institute followed by postdoctoral fellowship training in neuromuscular diseases with Howard Hughes Medical Institute at the University of Iowa.